Search Results - "Foster, Julie M."

Refine Results
  1. 1
  2. 2
  3. 3
  4. 4

    PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: A children's oncology group report by Skapek, Stephen X., Anderson, James, Barr, Frederic G., Bridge, Julia A., Gastier-Foster, Julie M., Parham, David M., Rudzinski, Erin R., Triche, Timothy, Hawkins, Douglas S.

    Published in Pediatric blood & cancer (01-09-2013)
    “…Background Rhabdomyosarcoma (RMS) is divided into two major histological subtypes: alveolar (ARMS) and embryonal (ERMS), with most ARMS expressing one of two…”
    Get full text
    Journal Article
  5. 5
  6. 6
  7. 7
  8. 8

    IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients by Pulsipher, Michael A., Carlson, Chris, Langholz, Bryan, Wall, Donna A., Schultz, Kirk R., Bunin, Nancy, Kirsch, Ilan, Gastier-Foster, Julie M., Borowitz, Michael, Desmarais, Cindy, Williamson, David, Kalos, Michael, Grupp, Stephan A.

    Published in Blood (28-05-2015)
    “…Positive detection of minimal residual disease (MRD) by multichannel flow cytometry (MFC) prior to hematopoietic cell transplantation (HCT) of patients with…”
    Get full text
    Journal Article
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20

    Homozygous variants in AMPD2 and COL11A1 lead to a complex phenotype of pontocerebellar hypoplasia type 9 and Stickler syndrome type 2 by Abreu, Nicolas J., Koboldt, Daniel C., Gastier‐Foster, Julie M., Dave‐Wala, Ashita, Flanigan, Kevin M., Waldrop, Megan A.

    “…Pontocerebellar hypoplasia type 9 (PCH9) is an autosomal recessive neurodevelopmental disorder caused by pathogenic variants in the AMPD2 gene. We evaluated…”
    Get full text
    Journal Article